SeaStar Medical 4/16/2024 Earnings Report

SeaStar Medical EPS Results

• Actual EPS: -$4.75
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

SeaStar Medical Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

SeaStar Medical Announcement Details

• Date: 4/16/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

SeaStar Medical (NASDAQ:ICU) is a medical device company focused on the design, development and commercialization of minimally invasive surgical access systems. The company’s product platforms aim to improve patient outcomes in transcatheter heart valve replacement and repair procedures by offering precise, low-profile access to vascular structures. SeaStar Medical’s devices are engineered to streamline procedural workflows and reduce complication rates associated with large-bore arterial punctures.

The flagship offering is the SPIDER Micro-Invasive Transcatheter Aortic Valve Replacement (TAVR) Access System, designed to facilitate controlled, hemostatic entry and closure during valve replacement procedures. In addition, the company markets the S-Access Micro-Puncture Kits, which include 18- and 22-gauge needle sets and specialty sheaths to support a broad range of diagnostic and interventional cardiology and endovascular therapies. These platforms are cleared by the U.S. Food and Drug Administration and carry CE mark approval for commercial distribution in Europe.

SeaStar Medical serves hospitals and cardiovascular centers across North America and select international markets through a combination of direct sales and distributor partnerships. The company’s offerings are used in high-volume structural heart programs as well as catheterization laboratories pursuing next-generation percutaneous interventions. In parallel, SeaStar continues to advance its pipeline of access and closure technologies for mitral and tricuspid valve repair procedures, reflecting its commitment to addressing growing clinical need in structural heart disease.

Founded in 2007 and headquartered in Morrisville, North Carolina, SeaStar Medical was built on the vision of improving procedural safety in minimally invasive cardiovascular interventions. The company’s leadership team comprises seasoned medical device executives and clinical advisors with extensive experience at leading cardiovascular technology firms. This expertise underpins SeaStar Medical’s focus on innovation, quality manufacturing and strategic market expansion.